Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.
You may also be interested in...
Deal Watch: Taking Care Of Business Before J.P. Morgan
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
A two-year patent infringement case reached a conclusion with the Delhi High Court favoring Natco in a dispute over generic versions of Teva’s top-selling MS drug. If the court had sided with Teva, launch plans for the United States may have been delayed for Natco’s partner Mylan.